Table 3 |
|||
|
Endothelial, T-cell and fibroblast activation markers in early SSc, UCTD patients and controls |
|||
|
Biomarker |
Early SSc (n = 21) |
UCTD (n = 24) |
Controls† (n = 25) |
|
|
|||
|
sE-selectin (pg/ml) median (range) |
0.732 (0.35 to 1.2) |
0.87 (0.32 to 1.99) # |
0.806 (0.4 to 1.76) |
|
sIL-2Rα (pg/ml) median (range) |
239 (66.7 to 1,002) |
346 (14.3 to 931) |
301 (17.9 to 807) |
|
ICTP (μg/l) median (range) |
3.998 (1.88 to 10.5)*; ° |
2.86 (1.17 to 4.25) |
3.21 (1.39 to 5.27) |
|
PIIINP (μg/l) median (range) |
1.491 (0.002 to 5.43) |
1.66 (0.01 to 2.98) |
1.65 (0.35 to 7.49) |
|
|
|||
|
ICTP, carboxyterminal telopeptide of type I collagen; IL-2Rα, interleukin-2 receptor alpha; PIIINP, aminoterminal propeptide of type III collagen; s, soluble; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease. † Affected by osteoarthritic or primary fibromyalgia syndrome. * P < 0.05 early SSc vs controls;°P < 0.05 early SSc vs UCTD; #P < 0.05 UCTD vs early SSc (P = 0.07 vs controls) |
|||
|
Valentini et al. Arthritis Research & Therapy 2012 14:R188 doi:10.1186/ar4019 |
|||